AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 221 filers reported holding AMICUS THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.76 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $181,573,994 | -3.1% | 14,934,021 | +0.1% | 0.12% | +1.7% |
| Q2 2023 | $187,417,974 | +24.2% | 14,923,588 | +9.6% | 0.12% | +17.0% |
| Q1 2023 | $150,935,079 | -9.7% | 13,610,435 | -0.6% | 0.10% | -16.0% |
| Q4 2022 | $167,201,808 | +8.3% | 13,694,549 | -53.7% | 0.12% | +3.5% |
| Q3 2022 | $154,421,267 | -14.3% | 29,552,230 | +76.1% | 0.12% | -7.3% |
| Q2 2022 | $180,236,000 | +21.8% | 16,780,141 | +7.4% | 0.12% | +74.6% |
| Q1 2022 | $147,957,000 | +29.9% | 15,622,613 | +58.5% | 0.07% | +51.1% |
| Q4 2021 | $113,878,000 | +69.0% | 9,857,881 | +39.7% | 0.05% | +62.1% |
| Q3 2021 | $67,378,000 | +40.1% | 7,054,208 | +41.4% | 0.03% | +38.1% |
| Q2 2021 | $48,092,000 | -45.8% | 4,988,587 | -44.5% | 0.02% | -48.8% |
| Q1 2021 | $88,762,000 | -65.8% | 8,984,055 | -20.1% | 0.04% | -66.1% |
| Q4 2020 | $259,701,000 | +30.4% | 11,247,208 | -20.3% | 0.12% | +16.3% |
| Q3 2020 | $199,181,000 | +12.0% | 14,106,259 | +19.6% | 0.10% | +4.0% |
| Q2 2020 | $177,849,000 | +65.6% | 11,793,759 | +1.4% | 0.10% | +35.1% |
| Q1 2020 | $107,423,000 | +2.5% | 11,625,924 | +8.1% | 0.07% | +37.0% |
| Q4 2019 | $104,789,000 | +19.4% | 10,758,616 | -1.7% | 0.05% | +12.5% |
| Q3 2019 | $87,789,000 | -35.3% | 10,946,235 | +0.7% | 0.05% | -35.1% |
| Q2 2019 | $135,695,000 | -9.8% | 10,872,979 | -1.7% | 0.07% | -10.8% |
| Q1 2019 | $150,363,000 | +41.7% | 11,056,142 | -0.2% | 0.08% | +22.1% |
| Q4 2018 | $106,085,000 | -0.4% | 11,073,584 | +25.7% | 0.07% | +19.3% |
| Q3 2018 | $106,469,000 | -16.7% | 8,806,359 | +7.7% | 0.06% | -21.9% |
| Q2 2018 | $127,746,000 | -0.6% | 8,178,387 | -4.3% | 0.07% | -3.9% |
| Q1 2018 | $128,537,000 | +12.8% | 8,546,339 | +8.0% | 0.08% | +8.6% |
| Q4 2017 | $113,921,000 | +1.6% | 7,916,701 | +6.5% | 0.07% | -2.8% |
| Q3 2017 | $112,109,000 | +58.4% | 7,434,314 | +5.8% | 0.07% | +50.0% |
| Q2 2017 | $70,762,000 | – | 7,027,010 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |